ArticleScientific reports2026
Ablation of cancer cell secreted neuropeptide PTHLH/PTHrP provokes anti-tumor immunity in murine tongue squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral cancer in the era of precision medicine: molecular targets and technological innovations.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra-tumor nerve infiltration has been correlated with poor prognosis of tumor, particularly in head and neck squamous cell carcinoma (HNSCC). While emerging evidence highlights the critical role of neuroimmune crosstalk in tumor progression and immunosuppression, the molecular mediators of this axis remain poorly understood. This study has identified cancer cell-secreted PTHLH/PTHrP as a key regulator of this neuroimmune network through integrated transcriptomic analysis, CRISPR-mediated knockout, and parallel preclinical models in immunodeficient (BALB/c nude) and immunocompetent (C57BL/6J) mice. Our finding revealed significant higher expression of PTHLH correlated with neuroimmune factors and poor prognosis in immunotherapy outcome. Genetic ablation of PTHLH significantly altered the expression of neurotrophic factors essential for intra-tumoral nerve growth. Strikingly, while PTHLH knockout showed no significant anti-tumor response in vitro and in immunodeficient mice, it dramatically reduced tumor burden in immunocompetent hosts. Comprehensive immune profiling further demonstrated enhanced immunoreactivity (increased CD8 + and CD4 + T cells) alongside reduced immunosuppression (decreased FOXP3 + Tregs and PD-L1 expression) in PTHLH-deficient tumors. Moreover, these tumors also showed lower expression of tumor proliferative and neuron markers. Together these findings established cancer cell secreted PTHLH as a critical mediator of immunosuppression and neuron infiltrations in HNSCC, particularly in tongue tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.